Literature DB >> 28283564

Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014.

Majken Linnemann Jensen1, Frederik Persson2, Gregers S Andersen1, Martin Ridderstråle1, John J Nolan1, Bendix Carstensen1, Marit E Jørgensen1,3.   

Abstract

Entities:  

Year:  2017        PMID： 28283564     DOI： 10.2337/dc16-2793

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  10 in total

1.  Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.

Authors:  Jenny E Blau; Sri Harsha Tella; Simeon I Taylor; Kristina I Rother
Journal:  Diabetes Metab Res Rev       Date:  2017-09-29       Impact factor: 4.876

2.  Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis.

Authors:  Marta Brandão Calçada; Luís Fernandes; Rita Soares Costa; Sara Montezinho; Filipa Martins Duarte; Luísa Frutuoso; Ana Raquel Freitas
Journal:  Clin Pract       Date:  2021-04-06

3.  Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.

Authors:  Xin-Lin Zhang; Qing-Qing Zhu; Yu-Han Chen; Xue-Ling Li; Fu Chen; Jian-An Huang; Biao Xu
Journal:  J Am Heart Assoc       Date:  2018-01-20       Impact factor: 5.501

4.  Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.

Authors:  Sang Mok Yeo; Hayeon Park; Jin Hyuk Paek; Woo Yeong Park; Seungyeup Han; Sung Bae Park; Kyubok Jin
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

5.  Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.

Authors:  Jennifer R Donnan; Catherine A Grandy; Eugene Chibrikov; Carlo A Marra; Kris Aubrey-Bassler; Karissa Johnston; Michelle Swab; Jenna Hache; Daniel Curnew; Hai Nguyen; John-Michael Gamble
Journal:  BMJ Open       Date:  2019-02-01       Impact factor: 2.692

6.  Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II.

Authors:  Timothy M E Davis; Wendy Davis
Journal:  BMJ Open Diabetes Res Care       Date:  2020-03

7.  Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.

Authors:  Lu Wang; Erica A Voss; James Weaver; Laura Hester; Zhong Yuan; Frank DeFalco; Martijn J Schuemie; Patrick B Ryan; Don Sun; Amy Freedman; Maria Alba; Joan Lind; Gary Meininger; Jesse A Berlin; Norman Rosenthal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-27       Impact factor: 2.890

8.  Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.

Authors:  Michael Fralick; Donald A Redelmeier; Elisabetta Patorno; Jessica M Franklin; Fahad Razak; Tara Gomes; Sebastian Schneeweiss
Journal:  J Gen Intern Med       Date:  2021-02-09       Impact factor: 6.473

9.  Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.

Authors:  John A D'Elia; Alissa R Segal; George P Bayliss; Larry A Weinrauch
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-06-15

Review 10.  New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Authors:  Claire C J Dekkers; Ron T Gansevoort; Hiddo J L Heerspink
Journal:  Curr Diab Rep       Date:  2018-03-27       Impact factor: 4.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.